Saturday 17 October 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAG Healthcare Biotechnology
Adagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024. Insiders bought in the last twelve months.
2.06
0.34
−14.17%
Follow ADAG
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.30 | 2.29 | 3.07 | 5.02 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
14.94% | 6.83% | 2.36% | 0.99% | |
Debt/Equity |
0.26 | 0.12 | 0.05 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.05) | (0.01) | (0.04) | (0.86) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(29.73) | (11.13) | (15.67) | (14.87) | |
Working Capital |
49.59 | 36.85 | 52.20 | 106.05 | |
Capital Expenditures |
(0.03) | 0.00 | (0.02) | (0.15) | |
Net Current Asset Value |
49.03 | 36.76 | 34.46 | 88.29 | |
| Other line items | |||||
Quick Ratio |
2.23 | 2.20 | 2.96 | 4.86 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.31 | 0.20 | 0.12 | 0.09 | |
Average Payables |
3.95 | 4.06 | 2.99 | 9.45 | |
Average Assets |
120.83 | 100.91 | 97.00 | 117.18 | |
Average Common Equity |
66.81 | 60.35 | 52.95 | 73.02 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates